# US 2003/0225069 A1 · Aza-benzothiopyranoindazoles with antitumor activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0225069 A1
- Document ID: US20030225069A1
- Status: Published application
- Kind: A1
- Application number: 10/096,421
- Filed: 2002-03-12
- Published: 2003-12-04
- Earliest claimed: 2002-03-12
- Assignees: Albany Molecular Research, Inc.
- Inventors: Simon N. Haydar
- Web page: https://patentgrep.com/patent/US20030225069A1

## CPC

- C07D 495/16: Peri-condensed systems
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a group of aza-anthrapyrazole compounds having antitumor activity, and processes for their preparation. Compositions containing the aza-anthrapyrazole compounds and methods of treating tumors and cancer in mammals with the compounds of the present invention are also disclosed.

## Claims

### Claim 1

A compound having the formula:
139
where:
W is selected from the group consisting of S, SO, and SO2;
Q is a 5- or 6-membered aromatic ring having at least one atom selected from the group consisting of N and S;
A is selected from the group consisting of: hydrogen; C1-C4 linear, branched, or cyclic alkyl which is substituted or unsubstituted; C1-C4 linear or branched alkoxy which is substituted or unsubstituted; hydroxy; C(O)H; C(O)OR,; SO2R1; (CH2)nNH(CH2)mCH3; (CH2)nN((CH2)mCH3)(CH2)pCH3; and (CH2)nD;
B is selected in the group consisting of: hydrogen; C1-C4 linear, branched, or cyclic alkyl which is substituted or unsubstituted; C1-C4 linear or branched alkoxy which is substituted or unsubstituted; hydroxy; (CH2)nNH(CH2)mCH3; (CH2)nN((CH2)mCH3)(CH2)pCH3; and (CH2)nD;
R1 is selected from a group consisting of C1-C10 alkyl, phenyl, and phenyl alkyl, as free bases;
n is 2-3;
m is 0-3;
p is 0-3; and
D is selected from the group consisting of: hydroxy; C1-C4 linear or branched alkoxy which is substituted or unsubstituted; and a 5- or 6-member aromatic or non-aromatic heterocyclic ring containing a sulfur, oxygen, or nitrogen heteroatom or
pharmaceutically acceptable salts.

### Claim 2 (depends on 1)

A compound according to claim 1, where the compound has the following formula:
140
where:
one or more of X, Y, Z, or T═N; or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 2)

A compound according to claim 2, where the compound has the following formula:
141
or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 2)

A compound according to claim 2, where the compound has the following formula:
142
or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 2)

A compound according to claim 2, where the compound has the following formula:
143
or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 2)

A compound according to claim 2, where the compound has the following formula:
144
or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 1)

A compound according to claim 1, where the compound has the following formula:
145
a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 1)

A compound according to claim 1, where the compound has the following formula:
146
where:
X, Y, or Z═S; or
a pharmaceutically acceptable salt thereof.

### Claim 9 (depends on 8)

A compound according to claim 8, where the compound has the following formula:
147
or a pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 8)

A compound according to claim 8, where the compound has the following formula:
148
or a pharmaceutically acceptable salt thereof.

### Claim 11 (depends on 8)

A compound according to claim 8, where the compound has the following formula:
149
or a pharmaceutically acceptable salt thereof.

### Claim 12

A process for preparation of a product compound of the formula:
150
where:
one or more of X, Y, Z, or T═N;
W is selected from the group consisting of S, SO, and SO2;
A is selected from the group consisting of: hydrogen; C1-C4 linear, branched, or cyclic alkyl which is substituted or unsubstituted; C1-C4 linear or branched alkoxy which is substituted or unsubstituted; hydroxy; C(O)H, C(O)OR1, SO2R1; (CH2)nNH(CH2)mCH3; (CH2)nN((CH2)mCH3)(CH2)pCH3; and (CH2)nD;
B is selected from the group consisting of: hydrogen; C1-C4 linear, branched, or cyclic alkyl which is substituted or unsubstituted; C1-C4 linear or branched alkoxy which is substituted or unsubstituted; hydroxy; (CH2)nNH(CH2)mCH3; (CH2)nN((CH2)mCH3)(CH2)pCH3; and (CH2)nD;
R1 is selected from a group consisting of C1-C10 alkyl, phenyl, and phenyl alkyl, as free bases;
n is 2-3;
m is 0-3;
p is 0-3; and
D is selected from the group consisting of: hydroxy; C1-C4 linear or branched alkoxy which is substituted or unsubstituted; and a 5- or 6-member aromatic or non-aromatic heterocyclic ring containing a sulfur, oxygen, or nitrogen heteroatom; or
pharmaceutically acceptable salts thereof, said process comprising:
transforming a first intermediate compound of the formula:
151
under conditions effective to form the product compound.

### Claim 13 (depends on 12)

The process according to claim 12 further comprising:
reacting a second intermediate compound of the formula:
152
with formamide/formic acid under conditions effective to form the first intermediate compound.

### Claim 14 (depends on 13)

The process according to claim 13 further comprising:
reacting a third intermediate compound of the formula:
153
under conditions effective to form the second intermediate compound, wherein U′ is I, F, Cl, Br, or H.

### Claim 15 (depends on 14)

The process according to claim 14 further comprising:
reacting a fourth intermediate compound of the formula:
154
where U is I, Br, F or Cl,
in the presence of NH2NHB, under conditions effective to form a mixture comprising the third intermediate compound.

### Claim 16 (depends on 15)

The process according to claim 15 further comprising:
reacting a fifth intermediate compound of the formula:
155
under conditions effective to form a mixture comprising the fourth intermediate compound.

### Claim 17 (depends on 16)

The process according to claim 16, further comprising:
reacting a sixth intermediate compound of the formula:
156
with a seventh intermediate compound of the formula:
157
under conditions effective to form the fifth intermediate compound.

### Claim 18 (depends on 16)

The process according to claim 16 further comprising:
reacting an eighth intermediate compound of the formula:
158
with NaNO2 and HU under conditions effective to form the sixth intermediate compound.

### Claim 19 (depends on 18)

The process according to claim 18 further comprising:
reacting a ninth intermediate compound of the formula:
159
under conditions effective to form the eighth intermediate compound.

### Claim 20 (depends on 19)

The process according to claim 19 further comprising:
reacting a tenth intermediate compound of the formula:
160
under conditions effective to form the ninth intermediate compound.

### Claim 21 (depends on 20)

The process according to claim 20 further comprising:
reacting an eleventh intermediate compound of the formula:
161
under conditions effective to form the tenth intermediate compound.

### Claim 22 (depends on 21)

The process according to claim 21, where Y═N.

### Claim 23 (depends on 21)

The process according to claim 21, where T═N.

### Claim 24 (depends on 21)

The process according to claim 21 further comprising:
reacting the product compound under conditions effective to form a second product compound having the formula:
162

### Claim 25 (depends on 15)

A process according to claim 15, where Z═Y═N, and where said fourth intermediate compound is prepared by the process comprising:
reacting a fifteenth intermediate compound of the formula:
163
with P2S5-pyridine under conditions effective to form the fourth intermediate compound.

### Claim 26 (depends on 25)

The process according to claim 25 further comprising:
reacting a sixteenth intermediate compound of the formula:
164
with AlCl3-toulene under conditions effective to form the fifteenth intermediate compound.

### Claim 27 (depends on 26)

The process according to claim 26 further comprising:
reacting a seventeenth intermediate compound of the formula:
165
under conditions effective to form the fifteenth intermediate compound.

### Claim 28 (depends on 27)

The process according to claim 27 further comprising:
reacting a eighteenth intermediate compound of the formula:
166
under conditions effective to form the seventeenth intermediate compound.

### Claim 29 (depends on 28)

The process according to claim 28 further comprising:
reacting an nineteenth intermediate compound of the formula:
167
under conditions effective to form the eighteenth intermediate compound.

### Claim 30 (depends on 29)

The process according to claim 29 further comprising:
reacting a twentieth intermediate compound of the formula:
168
under conditions effective to form the nineteenth intermediate compound.

### Claim 31 (depends on 30)

The process according to claim 30 further comprising:
reacting a twenty-first intermediate compound of the formula:
169
under conditions effective to form the twentieth intermediate compound.

### Claim 32 (depends on 31)

The process according to claim 31 further comprising:
reacting a twenty-second intermediate compound of the formula:
170
with a twenty-third intermediate compound of the formula:
171
under conditions effective to form the twenty-first intermediate compound.

### Claim 33

A process for preparation of a product compound of the formula:
172
where:
A is selected from the group consisting of: hydrogen; C1-C4 linear, branched, or cyclic alkyl which is substituted or unsubstituted; C1-C4 linear or branched alkoxy which is substituted or unsubstituted; hydroxy; C(O)H; C(O)OR1; SO2R1; (CH2)nNH(CH2)mCH3; (CH2)nN((CH2)mCH3)(CH2)pCH3; and (CH2)nD;
B is selected in the group consisting of: hydrogen; C1-C4 linear, branched, or cyclic alkyl which is substituted or unsubstituted; C1-C4 linear or branched alkoxy which is substituted or unsubstituted; hydroxy; (CH2)nNH(CH2)mCH3; (CH2)nN((CH2)mCH3)(CH2)pCH3; and (CH2)nD;
R1 is selected from a group consisting of C1-C10 alkyl, phenyl, and phenyl alkyl, as free bases;
n is 2-3;
m is 0-3;
p is 0-3; and
D is selected from the group consisting of: hydroxy; C1-C4 linear or branched alkoxy which is substituted or unsubstituted; and a 5- or 6-member aromatic or non-aromatic heterocyclic ring containing a sulfur, oxygen, or nitrogen heteroatom; or
a pharmaceutically acceptable salt thereof, said process comprising:
transforming a first intermediate compound of the formula:
173
under conditions effective to form the product compound.

### Claim 34 (depends on 33)

The process according to claim 33 further comprising:
reacting a second intermediate compound of the formula:
174
under conditions effective to form the first intermediate compound.

### Claim 35 (depends on 34)

The process according to claim 34 further comprising:
reacting a third intermediate compound of the formula:
175
under conditions effective to form the second intermediate compound.

### Claim 36 (depends on 35)

The process according to claim 35 further comprising:
reacting a fourth intermediate compound of the formula:
176
under conditions effective to form the third intermediate compound.

### Claim 37

A process for preparation of a product compound of the formula:
177
where:
A is selected from the group consisting of: hydrogen; C1-C4 linear, branched, or cyclic alkyl which is substituted or unsubstituted; C1-C4 linear or branched alkoxy which is substituted or unsubstituted; hydroxy; C(O)H; C(O)OR1; SO2R1; (CH2)nNH(CH2)mCH3; (CH2)nN((CH2)mCH3)(CH2)pCH3; and (CH2)nD;
B is selected in the group consisting of: hydrogen; C1-C4 linear, branched, or cyclic alkyl which is substituted or unsubstituted; C1-C4 linear or branched alkoxy which is substituted or unsubstituted; hydroxy; (CH2)nNH(CH2)mCH3; (CH2)nN((CH2)mCH3)(CH2)pCH3; and (CH2)nD;
R1 is selected from a group consisting of C1-C10 alkyl, phenyl, and phenyl alkyl, as free bases;
n is 2-3;
m is 0-3;
p is 0-3;
E is OCH3 or Cl; and
D is selected from the group consisting of: hydroxy; C1-C4 linear or branched alkoxy which is substituted or unsubstituted; and a 5- or 6-member aromatic or non-aromatic heterocyclic ring containing a sulfur, oxygen, or nitrogen heteroatom; or
a pharmaceutically acceptable salt thereof, said process comprising:
transforming a first intermediate compound of the formula:
178
under conditions effective to form the product compound wherein E is Cl.

### Claim 38 (depends on 37)

The process according to claim 37 further comprising:
reacting a second intermediate compound of the formula:
179
under conditions effective to form the first intermediate compound.

### Claim 39 (depends on 38)

The process according to claim 38 further comprising:
reacting a second intermediate compound of the formula:
180
under conditions effective to form the product compound, where E is OCH3.

### Claim 40 (depends on 38)

The process according to claim 38 further comprising:
reacting a third intermediate compound of the formula:
181
under conditions effective to form the second intermediate compound.

### Claim 41 (depends on 40)

The process according to claim 40 further comprising:
reacting a fourth intermediate compound of the formula:
182
under conditions effective to form the third intermediate compound.

### Claim 42 (depends on 41)

The process according to claim 41 further comprising:
reacting a fifth intermediate compound of the formula:
183
under conditions effective to form the fourth intermediate compound.

### Claim 43 (depends on 42)

The process according to claim 42 further comprising:
reacting a sixth intermediate compound of the formula:
184
under conditions effective to form the fifth intermediate compound.

### Claim 44 (depends on 43)

The process according to claim 43 further comprising:
reacting a seventh intermediate compound of the formula:
185
under conditions effective to form the sixth intermediate compound.

### Claim 45 (depends on 44)

The process according to claim 44 further comprising:
reacting a eighth intermediate compound of the formula:
186
under conditions effective to form the seventh intermediate compound.

### Claim 46 (depends on 1)

A method for inhibiting cell proliferation in mammals comprising:
administering a therapeutically effective amount of the compound of claim 1 to the mammal.

### Claim 47 (depends on 46)

The method of claim 46, where the compound is administered to a mammal suffering from a cell proliferation disorder selected from the group consisting of rheumatoid arthritis, lupus, type 1 diabetes, multiple sclerosis, cancer, restenosis, gout, and other proliferative diseases involving abnormal cellular proliferation.

### Claim 48 (depends on 47)

The method of claim 47, where the cellular proliferation disorder is cancer.

### Claim 49 (depends on 47)

The method of claim 47, where the cellular proliferation disorder is restenosis.

### Claim 50 (depends on 47)

The method of claim 47, where the cellular proliferation disorder is type 1 diabetes.

### Claim 51 (depends on 47)

The method of claim 47, where the mammal is human.

### Claim 52 (depends on 1)

A pharmaceutical composition of matter comprising the compound of claim 1 and one or more pharmaceutical excipients.
